氨柔比星用于小细胞肺癌二线治疗的荟萃分析

目的 系统评价氨柔比星治疗小细胞肺癌（small-cell lung cancer， SCLC）的疗效及安全性。方法 检索PubMed、EMBASE、CNKI及The Cochrane Library等数据库，收集有关氨柔比星治疗SCLC的研究；主要结局指标包括总有效率（overall response rate，ORR）、无进展生存率（progression free survival， PFS）、总生存率（overall survival， OS）及不良事件。结果 共有6项研究纳入，荟萃分析（Meta分析）显示，氨柔比星应用于SCLC二线治疗时的总有效率显著高于对照组RR 1.72，95% CI（1.39，2.14），P=0.000]，但总生存率HR 0.93，95% CI（0.81，1.07），P=0.405]和无进展生存率HR 0.98，95% CI（0.83，1.17），P=0.456]与对照组相比无明显差异。结论 氨柔比星治疗SCLC的总有效率高于对照组，且PFS和OS与对照组相比无显著性差异（P=0.405，P=0.456），因此，氨柔比星可作为SCLC的二线治疗药物。

Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer(SCLC).Methods PubMed, Embase, the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity.Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control groupRR 1.72,95% CI (1.39, 2.14),P=0.000], the OS, PFS and toxicity were no-inferior to the control group(P=0.405,P=0.456).Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.